Open AccessInitial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice
Author(s) -
Teiji Kuzuya,
Naoto Kawabe,
Senju Hashimoto,
Ryoji Miyahara,
Takuji Nakano,
Kazunori Nakaoka,
Hiroyuki Tanaka,
Yohei Miyachi,
Arisa Mii,
Yoshikatsu Tanahashi,
Yutaro Kato,
Atsushi Sugioka,
Yoshiki Hirooka
Publication year - 2021
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10012
Subject(s) - atezolizumab , lenvatinib , medicine , bevacizumab , adverse effect , hepatocellular carcinoma , oncology , refractory (planetary science) , gastroenterology , cancer , nivolumab , chemotherapy , sorafenib , immunotherapy , physics , astrobiology
The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice.